Mitochondrial signaling gives senescent cells a new route to chronic inflammation
Aging cells do more than sit idle. In this study, senescent cells remained metabolically active and kept feeding an inflammatory program long after the original stress should have passed. The work identifies a mitochondrial pathway that helps explain why chronic inflammation becomes more persistent with age, and why the inflammatory output of senescent cells can keep building instead of shutting off.
The biology is not subtle. Senescent cells, often called “zombie” cells because they stop dividing but do not die, can accumulate in aging tissues and release a senescence-associated secretory phenotype, or SASP. SASP is not a single molecule or a single pathway; it is a broad inflammatory state marked by secretion of cytokines and other factors that can spread tissue stress and reinforce age-related decline. By tracing how this inflammatory program is maintained, investigators at Sanford Burnham Prebys, Mayo Clinic, and collaborating institutions found a convergence between mitochondrial metabolism and epigenetic control of gene accessibility.
Acetyl-CoA and mitochondrial DNA leakage worked in tandem
The first signal came from metabolism. Mitochondria in senescent cells generated increased amounts of acetyl-CoA, a central metabolic molecule with direct epigenetic consequences. Acetyl-CoA interacts with histones, the spool-like proteins that package DNA. When histones are modified, chromatin can loosen, and genes that were previously harder to reach become more accessible to the cell’s transcriptional machinery. In this case, the exposed targets included genes linked to SASP.
One sentence captures the practical consequence: inflammatory genes became easier to switch on.
But greater accessibility alone did not fully explain why senescent cells keep secreting inflammatory molecules. A second mitochondrial defect was required. Damaged mitochondria can leak DNA and RNA into cellular compartments where those nucleic acids do not belong. The cell interprets that misplaced genetic material as a danger signal, which activates immune pathways and transcription factors that drive inflammatory gene expression. In effect, one mitochondrial abnormality opened the chromatin, while another supplied the alarm that turned those genes on.
This two-hit model matters biologically because it links energy metabolism to innate immune signaling. The mitochondrial compartment is not simply producing ATP; it is also shaping gene expression and innate immune tone. When both processes are active in senescent cells, the result is a self-reinforcing inflammatory state that can persist in aging tissue.
CTPI-2 reduced inflammation without removing the mitochondrial danger signal
Investigators tested whether interrupting one branch of this pathway could weaken the inflammatory program. They used CTPI-2, a drug that blocks a transport protein needed to move a component required for acetyl-CoA production. In mice, CTPI-2 reduced inflammation across multiple tissues and improved tissue function and healthspan during aging.
The intervention was selective rather than sweeping. The immune signals caused by leaking mitochondrial DNA and RNA were still present, but the metabolic arm of the pathway had been blunted. With less acetyl-CoA available, SASP genes were less accessible, and their inflammatory effects were reduced. The result supports a mechanistic distinction that is clinically relevant: the danger signal remained, yet the epigenetic door stayed harder to open.
That detail points to a plausible therapeutic strategy for age-related inflammation. Rather than trying to eliminate every senescent cell or suppress the immune system broadly, this approach aims at the metabolic state that allows senescent cells to sustain inflammatory gene expression. Such a strategy could, in principle, limit collateral tissue injury while preserving the host defense functions inflammation still needs.
Healthy aging depends on controlling inflammatory gene access, not only immune activation
The findings suggest that age-related inflammation may be driven not just by immune activation, but by the way metabolism reshapes chromatin inside senescent cells. This is an important distinction for aging biology. In many inflammatory settings, it is tempting to focus only on the extracellular signals that recruit immune cells. Here, the cell-intrinsic machinery mattered just as much: mitochondrial metabolism changed the accessibility of inflammatory genes, and mitochondrial damage supplied the signal that kept those genes active.
Peter Adams described senescent cells as metabolically active and carrying an inflammatory program that causes them to secrete inflammatory molecules. João Passos’s group set out to identify the molecular processes behind that program, and the work delivered a direct answer: two independent mitochondrial pathways converge to sustain SASP. One shapes DNA packaging through acetyl-CoA, and the other activates transcription through leaked nucleic acids. The convergence explains why senescent cells can remain inflammatory even after they have stopped dividing.
The paper, published in Nature, positions mitochondrial metabolism as a control point for aging biology. It also raises a clear translational question for later work: whether selective inhibitors like CTPI-2 can be developed into interventions that safely reduce chronic inflammatory burden in older organisms. The present data come from mice, so human efficacy and tolerability remain untested here. Even so, the mechanism is concrete, the functional readout is biologically meaningful, and the link between acetyl-CoA, chromatin accessibility, and senescence-associated inflammation gives aging research a new target to pursue.